CA-125 Test: Ovarian Cancer Marker Lab Guide

Table of Contents

  1. What is CA-125?
  2. Biology and Normal Values
  3. CA-125 in Ovarian Cancer
  4. Why CA-125 Alone Fails as a Screening Test
  5. PLCO and UKCTOCS: Definitive Screening Evidence
  6. HE4 and the ROMA Score
  7. Benign Causes of CA-125 Elevation
  8. CA-125 in BRCA1/2 Carriers and High-Risk Women
  9. Monitoring Treatment and Recurrence
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What is CA-125?

CA-125 (Cancer Antigen 125) is a high-molecular-weight mucin glycoprotein encoded by the MUC16 gene on chromosome 19p13. Also known as mucin-16 (MUC16), the name "CA-125" reflects the monoclonal antibody (OC125) used to detect it, first developed by Robert Bast Jr. and colleagues in 1981.

In healthy adults, CA-125 is expressed on the surface of mesothelial cells lining the peritoneum, pleura, pericardium, and fallopian tubes, as well as the surface epithelium of the ovary. A normal serum CA-125 is ≤35 U/mL, established by the original OC125 immunoradiometric assay; most second-generation assays retain the same cut-off.

CA-125 has several distinct clinical roles:

Back to Table of Contents

Biology and Normal Values

MUC16 is a large transmembrane protein with a heavily glycosylated extracellular domain containing repeating SEA (Sea Urchin Sperm Protein, Enterokinase, Agrin) modules. Proteolytic cleavage and shedding of this extracellular portion into circulation is what is measured as "CA-125" in blood. In cancer, overexpression and accelerated shedding dramatically raises serum concentrations.

Physiologically, CA-125 acts as a lubricant and anti-adhesion molecule at mesothelial surfaces — preventing cells from sticking together in the peritoneal cavity. Its circulating half-life is approximately 4–5 days, which is clinically important: after a successful surgical debulking or during active chemotherapy, CA-125 levels should fall predictably, and a slower-than-expected fall signals inadequate response.

Reference Ranges

Assay Generations

First-generation assays use only the OC125 antibody. Second-generation two-site assays (M11 + OC125) generally show better precision. These assays are not numerically interchangeable — always use the same assay platform for serial monitoring of an individual patient.

Back to Table of Contents

CA-125 in Ovarian Cancer

Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy. Approximately 80% of cases are serous, endometrioid, clear cell, or mucinous histology — grouped as "Type II" high-grade serous cancers dominate, accounting for most deaths. CA-125 performance varies significantly by histologic subtype:

Treatment Response Criteria

The Gynecologic Cancer InterGroup (GCIG) defines CA-125 response as ≥50% decrease from pre-treatment baseline, sustained for ≥28 days. Patients who normalize CA-125 (<35 U/mL) during first-line carboplatin/paclitaxel chemotherapy have significantly better progression-free and overall survival than those who do not normalize.

Surveillance After Complete Response

Standard surveillance (NCCN guidelines): CA-125 every 3 months for 2 years, then every 6 months for 3 years; a rising CA-125 on surveillance triggers CT imaging. CA-125 can precede clinical symptoms of recurrence by 3–6 months. However, the MRC OV05/EORTC 55955 trial demonstrated that triggering chemotherapy at CA-125-only recurrence — without waiting for symptoms — did not improve overall survival. Patients were simply exposed to platinum toxicity for longer without benefit. This finding is counterintuitive but robust, and means that rising CA-125 should prompt discussion and investigation, not immediate re-treatment.

CA-125 doubling time can help characterize recurrence: a doubling time shorter than 3 months suggests a more aggressive relapse.

Back to Table of Contents

Why CA-125 Alone Fails as a Screening Test

The idea of detecting ovarian cancer early via a simple blood test is appealing — ovarian cancer is often diagnosed late (Stage III–IV) precisely because early-stage disease is asymptomatic. Yet multiple large randomized trials have failed to show that CA-125-based screening saves lives. The core reasons are statistical and biological:

The USPSTF (2018, reaffirmed 2024) gives ovarian cancer screening with CA-125 or transvaginal ultrasound a Grade D recommendation — meaning the harms outweigh the benefits — for asymptomatic women without increased genetic risk. This is not a close call; it is a definitive recommendation against screening.

Back to Table of Contents

PLCO and UKCTOCS: Definitive Screening Evidence

Two large randomized controlled trials provide the definitive evidence base against CA-125 screening:

PLCO Trial (United States)

The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial randomized 78,216 women aged 55–74 to annual CA-125 + transvaginal ultrasound (TVUS) for up to 4 rounds vs. usual care. Results:

UKCTOCS Trial (United Kingdom)

The UK Collaborative Trial of Ovarian Cancer Screening was the largest ovarian cancer screening RCT ever conducted. It randomized 202,638 post-menopausal women to three arms:

  1. Multimodal screening (MMS): Annual CA-125 using the Risk of Ovarian Cancer Algorithm (ROCA) + TVUS when CA-125 trend was rising.
  2. Annual TVUS alone.
  3. No screening (control).

The ROCA algorithm is more sophisticated than a single CA-125 cut-off: it models the pattern of CA-125 change over time, triggering repeat testing when CA-125 is rising even within the normal range. This approach was developed specifically to improve on the limitations of a single threshold. Yet the 2021 final analysis (16 years of follow-up) found:

These two trials collectively enrolled over 280,000 women and followed them for up to 16 years. Their consistent null finding is the reason professional societies worldwide recommend against ovarian cancer screening in the general population.

Back to Table of Contents

HE4 and the ROMA Score

While CA-125 alone is not adequate for screening, combining it with a second biomarker significantly improves pre-surgical characterization of pelvic masses.

HE4 (Human Epididymis Protein 4)

HE4 is encoded by the WFDC2 gene and is overexpressed in ovarian and endometrial cancers. Key characteristics:

ROMA Score

The Risk of Ovarian Malignancy Algorithm (ROMA) is an FDA-cleared validated algorithm that combines CA-125 + HE4 + menopausal status to generate a numerical probability of epithelial ovarian cancer in a woman presenting with a pelvic mass:

In the pivotal validation study (Moore 2009, PMID 19582160), ROMA demonstrated 94.3% sensitivity and 75% specificity for detecting Stage III–IV EOC. The primary clinical application is pre-surgical triage: women with a newly detected pelvic mass who score high-risk on ROMA should be referred to a gynecologic oncologist (rather than a general gynecologist) for surgical evaluation — this routing decision affects staging adequacy and survival outcomes.

Important limitations: ROMA is not a diagnostic test and is not validated for cancer screening. It applies only to women who already have a pelvic mass identified by imaging.

OVA1 and Overa

OVA1 and its successor Overa are FDA-cleared multivariate index assays that incorporate CA-125 and HE4 along with additional protein biomarkers (transthyretin, apolipoprotein A1, beta-2 microglobulin for OVA1; transferrin and follicle-stimulating hormone for Overa). These panels offer modestly improved performance over ROMA alone for pre-surgical malignancy prediction and are used in the same clinical context.

Back to Table of Contents

Benign Causes of CA-125 Elevation

Understanding benign causes of CA-125 elevation is essential for avoiding unnecessary surgery. The following conditions commonly elevate CA-125, sometimes to levels that mimic advanced malignancy:

Gynecologic Conditions

Non-Gynecologic Conditions

Clinical Interpretation Rule

In pre-menopausal women with a pelvic mass, a CA-125 value up to 200 U/mL must be interpreted cautiously — endometriosis and PID are common mimics. Post-menopausal women have a narrower differential for elevated CA-125, and the threshold for surgical evaluation is appropriately lower.

Back to Table of Contents

CA-125 in BRCA1/2 Carriers and High-Risk Women

Women with germline BRCA1 or BRCA2 mutations face dramatically elevated ovarian cancer risk:

For many years, annual TVUS + CA-125 was standard surveillance for BRCA carriers. This practice has been largely abandoned based on the evidence from UKCTOCS and PLCO, which showed no mortality benefit even from optimized screening strategies.

Current NCCN/ACOG/SGO Recommendations (2024)

Lynch Syndrome

Women with Lynch syndrome (germline MLH1, MSH2, MSH6, or PMS2 mutations) face elevated risk of endometrial and, to a lesser degree, ovarian cancer. Annual endometrial sampling plus gynecologic exam is recommended. The utility of CA-125 in Lynch syndrome surveillance is uncertain and not currently supported by guideline-level evidence.

Back to Table of Contents

Monitoring Treatment and Recurrence

Monitoring ovarian cancer treatment is where CA-125 provides its clearest clinical value, despite the counterintuitive finding from MRC OV05 that acting immediately on a rising CA-125 does not improve survival.

During First-Line Chemotherapy

CA-125 is measured at baseline and before each cycle of carboplatin + paclitaxel. The GCIG criteria define treatment response as a ≥50% decrease from pre-treatment baseline sustained for ≥28 days. Patients who normalize CA-125 (<35 U/mL) achieve significantly better progression-free and overall survival than those whose CA-125 does not normalize.

CA-125 and Recurrence Timing: MRC OV05/EORTC 55955

The MRC OV05/EORTC 55955 trial (2010, PMID 20709966) enrolled 527 patients with CA-125-confirmed recurrence and randomized them to early chemotherapy (triggered by rising CA-125) vs. delayed treatment (until clinical symptoms or imaging evidence). Results:

The practical implication: inform patients when CA-125 is rising and engage them in shared decision-making about timing of reinvestigation — but do not automatically initiate chemotherapy based on biochemical recurrence alone. The GCIG biochemical recurrence definition (CA-125 on two consecutive measurements above 2× nadir) is a trigger for discussion and imaging, not necessarily immediate treatment.

Maintenance Therapies

Back to Table of Contents

Key Research Papers

Back to Table of Contents

Connections

Back to Table of Contents